DTaP-IPV/Hib Combined vaccine + DTaP-IPV vaccine and Hib vaccine + DTaP-IPV/Hib Combined vaccine
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Tetanus
Conditions
Tetanus, Diphtheria, Pertussis, Poliomyelitis, Bacterial Meningitis
Trial Timeline
Oct 1, 2014 → May 28, 2016
NCT ID
NCT02274285About DTaP-IPV/Hib Combined vaccine + DTaP-IPV vaccine and Hib vaccine + DTaP-IPV/Hib Combined vaccine
DTaP-IPV/Hib Combined vaccine + DTaP-IPV vaccine and Hib vaccine + DTaP-IPV/Hib Combined vaccine is a phase 3 stage product being developed by Sanofi for Tetanus. The current trial status is completed. This product is registered under clinical trial identifier NCT02274285. Target conditions include Tetanus, Diphtheria, Pertussis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02274285 | Phase 3 | Completed |
Competing Products
10 competing products in Tetanus